SOURCE: Amazon Biotech, Inc.

February 16, 2007 18:30 ET

Harbinger Research Issues Research Brief for Amazon Biotech Inc. With a Speculative Buy Rating and Price Target of $0.25

NEW YORK, NY -- (MARKET WIRE) -- February 16, 2007 -- Harbinger Research LLC, www.harbingerresearch.com, an independent research firm, issued a Research Brief today for Amazon Biotech, Inc. (OTCBB: AMZB), a development stage pharmaceutical/biotech company that is developing an all natural drug (AMZ 0026) for the treatment of HIV/AIDS.

The report provides a description of Amazon Biotech's business, industry, product, strategy, management team, and investment opportunities and risks. The report also includes a rating and price target.

The report is available free of charge at http://www.harbingerresearch.com/viewCompany.php?company=21.

About Harbinger Research, LLC:

Harbinger Research is a quality-leading New York based independent equity research company that provides insightful, in-depth equity research coverage and informational reports to smaller U.S. traded companies and the individuals and institutions that invest in them.

For further information on Harbinger Research, please visit www.harbingerresearch.com

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is the company's first such drug, which is to be used for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the FDA Fast Track program to market. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at: www.amazonbiotech.com.

Harbinger Research Contact:
Brian R. Connell, CFA
Chief Executive Officer
bconnell@harbingerresearch.com
Statement under the Private Securities Litigation Reform Act:

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.

Harbinger Research, LLC received US$5,000 from a third party in return for report authoring and distribution services.

Contact Information


  • Contact:
    LC Group
    Rick Lutz
    (404) 261-1196